Cretostimogene Grenadenorepvec

Summary

Cretostimogene Grenadenorepvec (CHEMBL5095454) is a phase-3 clinical-stage gene; indicated across 3 conditions including neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 3 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095454
Name	Cretostimogene Grenadenorepvec
Type	Gene
Max phase	3

Also known as: CG 0070, CG-0070, CG0070, Cretostimogen grenadenorepvec, Cretostimogene grenadenorepvec, CRETOSTIMOGENE GRENADENOREPVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
neoplasm	1	MONDO:0005070	EFO:0000616

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	2
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04452591	PHASE3	ACTIVE_NOT_RECRUITING	Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT06111235	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06567743	PHASE2	RECRUITING	Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT07283835	PHASE2	RECRUITING	Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT02365818	PHASE2	COMPLETED	Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
NCT04387461	PHASE2	COMPLETED	Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
NCT06253845	PHASE1	ACTIVE_NOT_RECRUITING	Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
NCT04610671	PHASE1	COMPLETED	Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
NCT06443944	Not specified	AVAILABLE	An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).